Literature DB >> 25925892

Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma.

Angela C Hirbe1, Sonika Dahiya2, Christopher A Miller3, Tiandao Li3, Robert S Fulton3, Xiaochun Zhang2, Sandra McDonald2, Katherine DeSchryver2, Eric J Duncavage2, Jessica Walrath4, Karlyne M Reilly4, Haley J Abel5, Melike Pekmezci6, Arie Perry7, Timothy J Ley3, David H Gutmann8.   

Abstract

PURPOSE: Malignant peripheral nerve sheath tumors (MPNST) occur at increased frequency in individuals with neurofibromatosis type 1 (NF1), where they likely arise from benign plexiform neurofibroma precursors. While previous studies have used a variety of discovery approaches to discover genes associated with MPNST pathogenesis, it is currently unclear what molecular events are associated with the evolution of MPNST from plexiform neurofibroma. EXPERIMENTAL
DESIGN: Whole-exome sequencing was performed on biopsy materials representing plexiform neurofibroma (n = 3), MPNST, and metastasis from a single individual with NF1 over a 14-year period. Additional validation cases were used to assess candidate genes involved in malignant progression, while a murine MPNST model was used for functional analysis.
RESULTS: There was an increasing proportion of cells with a somatic NF1 gene mutation as the tumors progressed from benign to malignant, suggesting a clonal process in MPNST development. Copy number variations, including loss of one copy of the TP53 gene, were identified in the primary tumor and the metastatic lesion, but not in benign precursor lesions. A limited number of genes with nonsynonymous somatic mutations (βIII-spectrin and ZNF208) were discovered, several of which were validated in additional primary and metastatic MPNST samples. Finally, increased βIII-spectrin expression was observed in the majority of MPNSTs, and shRNA-mediated knockdown reduced murine MPNST growth in vivo.
CONCLUSIONS: Collectively, the ability to track the molecular evolution of MPNST in a single individual with NF1 offers new insights into the sequence of genetic events important for disease pathogenesis and progression for future mechanistic study. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25925892      PMCID: PMC4573781          DOI: 10.1158/1078-0432.CCR-14-3049

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  63 in total

1.  Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation.

Authors:  G P Nielsen; A O Stemmer-Rachamimov; Y Ino; M B Moller; A E Rosenberg; D N Louis
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 2.  Survivin beyond physiology: orchestration of multistep carcinogenesis and therapeutic potentials.

Authors:  Kalliopi Ch Athanasoula; Helen Gogas; Katerina Polonifi; Aristeidis G Vaiopoulos; Aristidis Polyzos; Marina Mantzourani
Journal:  Cancer Lett       Date:  2014-02-19       Impact factor: 8.679

Review 3.  National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987.

Authors: 
Journal:  Neurofibromatosis       Date:  1988

4.  Biallelic inactivation of TP53 rarely contributes to the development of malignant peripheral nerve sheath tumors.

Authors:  R A Lothe; B Smith-Sørensen; M Hektoen; A E Stenwig; N Mandahl; G Saeter; F Mertens
Journal:  Genes Chromosomes Cancer       Date:  2001-02       Impact factor: 5.006

5.  Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis.

Authors:  Meena Upadhyaya; Gill Spurlock; Laura Thomas; Nick S T Thomas; Mark Richards; Viktor-Felix Mautner; David N Cooper; Abhijit Guha; Jim Yan
Journal:  Hum Mutat       Date:  2012-03-05       Impact factor: 4.878

6.  CXCR4 regulates growth of both primary and metastatic breast cancer.

Authors:  Matthew C P Smith; Kathryn E Luker; Joel R Garbow; Julie L Prior; Erin Jackson; David Piwnica-Worms; Gary D Luker
Journal:  Cancer Res       Date:  2004-12-01       Impact factor: 12.701

7.  Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms.

Authors:  David E Reuss; Antje Habel; Christian Hagenlocher; Jana Mucha; Ulrike Ackermann; Claudia Tessmer; Jochen Meyer; David Capper; Gerhard Moldenhauer; Victor Mautner; Pierre-Olivier Frappart; Jens Schittenhelm; Christian Hartmann; Christian Hagel; Kathrin Katenkamp; Iver Petersen; Gunhild Mechtersheimer; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2014-01-25       Impact factor: 17.088

8.  Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1.

Authors:  Yuqiang Fang; Abul Elahi; Ryan C Denley; Pulivarthi H Rao; Murray F Brennan; Suresh C Jhanwar
Journal:  Anticancer Res       Date:  2009-04       Impact factor: 2.480

9.  Trp53 haploinsufficiency modifies EGFR-driven peripheral nerve sheath tumorigenesis.

Authors:  Eric P Rahrmann; Branden S Moriarity; George M Otto; Adrienne L Watson; Kwangmin Choi; Margaret H Collins; Margaret Wallace; Beau R Webber; Colleen L Forster; Anthony E Rizzardi; Stephen C Schmechel; Nancy Ratner; David A Largaespada
Journal:  Am J Pathol       Date:  2014-05-13       Impact factor: 4.307

10.  Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis.

Authors:  Stine A Danielsen; Guro E Lind; Matthias Kolberg; Maren Høland; Bodil Bjerkehagen; Kirsten Sundby Hall; Eva van den Berg; Fredrik Mertens; Sigbjørn Smeland; Piero Picci; Ragnhild A Lothe
Journal:  Neuro Oncol       Date:  2014-07-19       Impact factor: 12.300

View more
  22 in total

1.  The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas.

Authors:  A Pemov; H Li; R Patidar; N F Hansen; S Sindiri; S W Hartley; J S Wei; A Elkahloun; S C Chandrasekharappa; J F Boland; S Bass; J C Mullikin; J Khan; B C Widemann; M R Wallace; D R Stewart
Journal:  Oncogene       Date:  2017-01-09       Impact factor: 9.867

2.  β-III-spectrin immunohistochemistry as a potential diagnostic tool with high sensitivity for malignant peripheral nerve sheath tumors.

Authors:  Angela C Hirbe; Xiaochun Zhang; Sonika Dahiya; Abigail Godec; John Chrisinger; Yu Tao; Jingqin Luo; David H Gutmann
Journal:  Neuro Oncol       Date:  2018-05-18       Impact factor: 12.300

3.  Chromosomal translocations inactivating CDKN2A support a single path for malignant peripheral nerve sheath tumor initiation.

Authors:  Cleofe Romagosa; Eduard Serra; Bernat Gel; Miriam Magallón-Lorenz; Juana Fernández-Rodríguez; Ernest Terribas; Edgar Creus-Batchiller; Anna Estival; Diana Perez Sidelnikova; Héctor Salvador; Alberto Villanueva; Ignacio Blanco; Meritxell Carrió; Conxi Lázaro
Journal:  Hum Genet       Date:  2021-05-31       Impact factor: 4.132

4.  Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival.

Authors:  Arjen H G Cleven; Ghadah A Al Sannaa; Inge Briaire-de Bruijn; Davis R Ingram; Matt van de Rijn; Brian P Rubin; Maurits W de Vries; Kelsey L Watson; Keila E Torres; Wei-Lien Wang; Sjoerd G van Duinen; Pancras C W Hogendoorn; Alexander J Lazar; Judith V M G Bovée
Journal:  Mod Pathol       Date:  2016-03-18       Impact factor: 7.842

5.  Immortalization of human normal and NF1 neurofibroma Schwann cells.

Authors:  Hua Li; Lung-Ji Chang; Debbie R Neubauer; David F Muir; Margaret R Wallace
Journal:  Lab Invest       Date:  2016-09-12       Impact factor: 5.662

6.  Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formation.

Authors:  Angela C Hirbe; Sonika Dahiya; Dinorah Friedmann-Morvinski; Inder M Verma; D Wade Clapp; David H Gutmann
Journal:  Oncotarget       Date:  2016-02-16

7.  Developing therapies for rare tumors: opportunities, challenges and progress.

Authors:  Diana Bradford; Karlyne M Reilly; Brigitte C Widemann; Abby Sandler; Shivaani Kummar
Journal:  Expert Opin Orphan Drugs       Date:  2015-12-09       Impact factor: 0.694

8.  Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use.

Authors:  Chetan Bettegowda; Meena Upadhayaya; D Gareth Evans; AeRang Kim; Dimitrios Mathios; Clemens O Hanemann
Journal:  Neurology       Date:  2021-07-06       Impact factor: 11.800

9.  Genomic Status of MET Potentiates Sensitivity to MET and MEK Inhibition in NF1-Related Malignant Peripheral Nerve Sheath Tumors.

Authors:  Jacqueline D Peacock; Matthew G Pridgeon; Elizabeth A Tovar; Curt J Essenburg; Megan Bowman; Zachary Madaj; Julie Koeman; Elissa A Boguslawski; Jamie Grit; Rebecca D Dodd; Vadim Khachaturov; Diana M Cardona; Mark Chen; David G Kirsch; Flavio Maina; Rosanna Dono; Mary E Winn; Carrie R Graveel; Matthew R Steensma
Journal:  Cancer Res       Date:  2018-05-02       Impact factor: 13.312

10.  Whole Exome Sequencing of Rapid Autopsy Tumors and Xenograft Models Reveals Possible Driver Mutations Underlying Tumor Progression.

Authors:  Tao Xie; Monica Musteanu; Pedro P Lopez-Casas; David J Shields; Peter Olson; Paul A Rejto; Manuel Hidalgo
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.